Based on the Halozyme Therapeutics Inc stock forecast from 7 analysts, the average analyst target price for Halozyme Therapeutics Inc is USD 62.33 over the next 12 months. Halozyme Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Halozyme Therapeutics Inc is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Halozyme Therapeutics Inc’s stock price was USD 46.96. Halozyme Therapeutics Inc’s stock price has changed by -2.17% over the past week, +2.62% over the past month and +29.08% over the last year.
No recent analyst target price found for Halozyme Therapeutics Inc
No recent average analyst rating found for Halozyme Therapeutics Inc
Company Overview Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. Read Less
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant huma...Read More
Frequently Asked Questions About Halozyme Therapeutics Inc (HALO) Stock
Based on ratings from 7 analysts Halozyme Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 12 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on HALO's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for HALO is USD 62.33 over the next 12 months. The maximum analyst target price is USD 70 while the minimum anlayst target price is USD 49.
HALO stock's Price/Earning ratio is 15.89.
Our analysis grades HALO stock's Price / Earning ratio at F. This means that HALO stock's Price/Earning ratio is above 67% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this HALO may be a overvalued for its sector.
The last closing price of HALO's stock was USD 46.96.
The most recent market capitalization for HALO is USD 6.11B.
Based on targets from 7 analysts, the average taret price for HALO is projected at USD 62.33 over the next 12 months.
This means that HALO's stock price may go up by +32.74% over the next 12 months.
We can't find any ETFs which contains Halozyme Therapeutics Inc's stock.
As per our most recent records Halozyme Therapeutics Inc has 373 Employees.
Halozyme Therapeutics Inc's registered address is 12390 El Camino Real, San Diego, CA, United States, 92130.
You can get more information about it from Halozyme Therapeutics Inc's website at https://halozyme.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Halozyme Therapeutics Inc (HALO) Stock
Based on ratings from 7 analysts Halozyme Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 12 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on HALO's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for HALO is USD 62.33 over the next 12 months. The maximum analyst target price is USD 70 while the minimum anlayst target price is USD 49.
HALO stock's Price/Earning ratio is 15.89.
Our analysis grades HALO stock's Price / Earning ratio at F. This means that HALO stock's Price/Earning ratio is above 67% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this HALO may be a overvalued for its sector.
The last closing price of HALO's stock was USD 46.96.
The most recent market capitalization for HALO is USD 6.11B.
Based on targets from 7 analysts, the average taret price for HALO is projected at USD 62.33 over the next 12 months.
This means that HALO's stock price may go up by +32.74% over the next 12 months.
We can't find any ETFs which contains Halozyme Therapeutics Inc's stock.
As per our most recent records Halozyme Therapeutics Inc has 373 Employees.
Halozyme Therapeutics Inc's registered address is 12390 El Camino Real, San Diego, CA, United States, 92130.
You can get more information about it from Halozyme Therapeutics Inc's website at https://halozyme.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HALO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
